SNBP released a 10Q the other day with eye-popping earnings for a $25m company.
The kicker? SNBP hasn't released any news highlighting the spectacular company growth yet.
Based on past quarters SNBP should issue a news release in the near future and Q3 was so spectacular the PR could be a major catalyst for the stock.
I can't stress enough the importance to do your homework on SNBPbefore Tuesday's opening bell:
- SNBP generated $1,073,550 net income for Q3 '09 vs. a loss of ($1,045,239) for Q3 '08;
- Revenues increased 120%;
- Operating expenses decreased 63%;
If you annualize SNBP's Q3 net income ($4.3m) then you realize thatSNBP is trading with a forward P/E ratio of 6!
What does SNBP do?
SNBP sells pharmaceuticals in China and has the production rights to 23 drugs on China's National Essential Drug List.
The company's flagship product, Cisatracurium Besylate, is a pre-surgical skeletal muscle relaxant and is the world's first bio-identical version of GlaxoSmithKline's (NYSE: GSK) Nimbex that costs 85% less.
Everyone in the CollegeStock Community should "do their homework" onSNBP before the markets open on Tuesday.
Once news hits the wire, the entire investment community will understand how spectacular SNBP's most recent quarter was.
No comments:
Post a Comment